Auf dieser Seite
01BMRN Preis
02Momentaufnahme
03Chart
05Über uns
06Performance
07Bewertung & Kennzahlen
14Erträge
15Vollständige Fundamentaldaten
16Erklärungen
17Institutionelle Eigentümer (13F)
18Aktivisten & 5%+-Eigentümer
19Unternehmensinsider
20ETF-Besitz
21Konsens
22Peers
23Nachrichten
25Handelssignale
26Meine Kennzahlen
BMRN BioMarin Pharmaceutical Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$57,18
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$49,2652-Wochen-Tief
$70,9852-Wochen-Hoch
Marktkapitalisierung (MRQ)
$11.07B
P/E (TTM)
146.6
EPS (TTM)
$0.39
Umsatz (TTM)
$3.41B
Ihre Abzeichen
52W-Spanne
$49–$71
Analystenbewertung
BUY
Kursziel
$92
P/E
146.6
ROE
1.2%
Nettogewinnmarge
2.1%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
BMRN Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$57.18
Marktkapitalisierung (MRQ)
$11.07B
P/E (TTM)
146.6
EPS (TTM)
$0.39
Umsatz (TTM)
$3.41B
ROE (TTM)
1.2%
Verschuldungsgrad (MRQ)
0.7
52W-Spanne
$49–$71
BMRN Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über BioMarin Pharmaceutical Inc. - Common Stock Unternehmensübersicht von Wikipedia
BioMarin Pharmaceutical ist ein US-amerikanisches Biotechnologieunternehmen mit Hauptsitz in San Rafael, Kalifornien. Es verfügt über Niederlassungen und Einrichtungen in den USA, Südamerika, Asien und Europa. Das Unternehmen ist spezialisiert auf lebensbedrohliche und seltene genetische Krankheiten. Das Kerngeschäft und das hauptsächliche Forschungsfeld von BioMarin sind Enzymersatztherapien. BioMarin war das erste Unternehmen, das Therapeutika für Mukopolysaccharidose Typ I (MPS I) durch Herstellung von Iduronidase (Aldurazyme, vertrieben von Genzyme Corporation) anbot. BioMarin war auch das erste Unternehmen, das Therapeutika gegen Phenylketonurie (PKU) anbot.
Ein weiterer Fokus von BioMarin ist die Gentherapie. So arbeitet das Unternehmen seit Jahren an der Option, die Hämophilie (Bluterkrankheit) mithilfe dieses Therapieprinzips zu behandeln. Im Unterschied zur konventionellen Therapie, die eine lebenslange Behandlung erfordert, soll die – einmalige – Gentherapie eine Heilung herbeiführen, auch wenn ca. 20–30 % Wirksamkeitsverlust nach 2–3 Jahren beobachtet wurde. Für die EU erfolgte die Zulassung 2022, in den USA im Juni 2023 mit der Indikation: für erwachsene Patienten mit schwerer Hämophilie A.
Geschichte
Das Unternehmen wurde 1997 von Christopher Starr und Grant W. Denison Jr. mit Hilfe einer Investition von 1,5 Mio. US-Dollar von Glyko Biomedical gegründet. Private Investoren stellten im selben Jahr Kapital in Höhe von mehr als 11 Millionen US-Dollar zur Verfügung. Das Unternehmen ist seit 1999 börsennotiert. Es startete 1997 eine klinische Studie für Aldurazyme, sein erstes Medikament zur Indikation von Mucopolysaccharidosis Typ I. Seit 2003 darf BioMarin dieses Medikament in Europa und Nordamerika kommerziell vertreiben.
BioMarin Pharmaceutical übernahm im Laufe der Zeit mehrere kleinere Unternehmen, darunter 2014 das niederländische Biotechnologieunternehmen Prosensa, welches für eine Summe von 840 Millionen US-Dollar übernommen wurde.
2019 berichteten mehrere Medien, dass BioMarin die Freigabe des mehrfach erfolgreich getesteten Arzneistoffes Sapropterin (Kuvan) verweigert hatte, um finanziell zu profitieren. Mehrere Personen wurden dadurch geschädigt. Ein Testpatient musste deshalb aufgrund von Phenylketonurie wieder dauerhaft behindert leben.
Produkte
Laronidase (Handelsname: Aldurazyme), zugelassen in den USA und der EU zur Behandlung der Mukopolysaccharidose Typ I. In Europa durch Genzyme vertrieben.
Galsulfase (Handelsname: Naglazyme) als Enzymersatztherapie zur Behandlung der Mukopolysaccharidose Typ VI (MPS VI).
Vosoritid zur Behandlung der Achondroplasie bei Kindern ab zwei Jahren.
Pipeline
Im Juli 2021 begann die Europäische Arzneimittelagentur (EMA) mit der Validierung des Zulassungsantrags von BioMarin für Valoctocogene Roxaparvovec zur Behandlung von schwerer Hämophilie A.
Im September 2021 stoppt die FDA eine klinische Phase 1/2 Gentherapie-Studie BMN 307 Phearless bei Erwachsenen mit Phenylketonurie (PKU) aufgrund vorläufiger präklinischer Studienergebnisse.
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheBiotechnology
Mitarbeiter3.221
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$3.22B2016-12-31 → 2025-12-31
EPS$1.802016-12-31 → 2025-12-31
Freier Cashflow$725M2016-12-31 → 2025-12-31
Nettogewinnmarge2.1%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | BMRN | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | 146.65-Jahres-Durchschnitt ≈11.8 | ≈11.8 | · | · | |
| P/S (TTM) | 3.25-Jahres-Durchschnitt ≈6.7 | ≈6.7 | 20.4 | Unterbewertet | |
| K/B (MRQ) | 1.85-Jahres-Durchschnitt ≈3.2 | ≈3.2 | 11.3 | Unterbewertet | |
| Kurs / FCF (TTM) | 15.05-Jahres-Durchschnitt ≈152.1 | ≈152.1 | · | · | |
| Kurs / Cashflow (TTM) | 12.95-Jahres-Durchschnitt ≈62.6 | ≈62.6 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | 7.75-Jahres-Durchschnitt ≈3.5 | ≈3.5 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | BMRN | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | 4.4%5-Jahres-Durchschnitt ≈7.8% | ≈7.8% | -30.6% | Spitzenklasse | |
| EBITDA-Marge (TTM) | 8.9%5-Jahres-Durchschnitt ≈12.0% | ≈12.0% | -30.6% | Spitzenklasse | |
| Vorgewinnmarge (TTM) | 4.4%5-Jahres-Durchschnitt ≈9.0% | ≈9.0% | -29.3% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | 2.1%5-Jahres-Durchschnitt ≈7.2% | ≈7.2% | -29.6% | Spitzenklasse | |
| ROA (TTM) | 0.76%5-Jahres-Durchschnitt ≈2.9% | ≈2.9% | -22.9% | Spitzenklasse | |
| ROE (TTM) | 1.2%5-Jahres-Durchschnitt ≈3.7% | ≈3.7% | 18.1% | Schwach | |
| ROIC | 4.9%5-Jahres-Durchschnitt ≈3.2% | ≈3.2% | 14.3% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | BMRN | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.7 | · | 0.3 | Hohe Verschuldung | |
| Liquiditätsgrad (MRQ) | 2.45-Jahres-Durchschnitt ≈4.4 | ≈4.4 | 3.2 | Geringe Liquidität | |
| Quick Ratio | 2.95-Jahres-Durchschnitt ≈2.1 | ≈2.1 | 1.8 | Geringe Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.6 | · | 0.6 | Im Einklang |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | BMRN | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 12.9%5-Jahres-Durchschnitt ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 15.4%5-Jahres-Durchschnitt ≈13.4% | ≈13.4% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 11.6% | · | · | · | |
| EPS YoY (EPS VjV) | -18.6%5-Jahres-Durchschnitt ≈50.5% | ≈50.5% | · | · | |
| Net Income YoY (Nettogewinn YoY) | -18.3%5-Jahres-Durchschnitt ≈51.6% | ≈51.6% | · | · | |
| EPS CAGR 3Y (EPS CAGR 3J) | 33.9% | · | · | · | |
| EPS CAGR 5Y (EPS CAGR 5J) | -16.7% | · | · | · | |
| Net Income CAGR 3Y (Nettoergebnis CAGR 3J) | 35.1% | · | · | · | |
| Net Income CAGR 5Y (Nettoergebnis CAGR 5J) | -16.4% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | BMRN | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.45-Jahres-Durchschnitt ≈0.4 | ≈0.4 | 0.4 | Im Einklang | |
| Inventory Turnover (Lagerumschlag) | 0.65-Jahres-Durchschnitt ≈0.6 | ≈0.6 | 1.0 | Unterdurchschnittlich | |
| Receivables Turnover (Forderungsumschlag) | 4.15-Jahres-Durchschnitt ≈4.5 | ≈4.5 | 5.1 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$1.0M | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-38.2%
Nächster Bericht
Okt 26, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 3, 2026 | $0.73 | $0.70 | 4.0% |
| 31. März 2026 | $0.54 | $0.77 | -29.5% | |
| 31. Dezember 2025 | $-0.24 | $0.64 | -137.7% | |
| 30. September 2025 | $-0.16 | $0.38 | -142.2% | |
| 30. Juni 2025 | $1.23 | $0.85 | 44.4% | |
| 31. März 2025 | $0.95 | $0.72 | 31.5% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $31.65 | $29.66 | $26.25 | $24.71 | $23.22 | $22.59 | $17.36 | $16.65 | $15.97 | $16.02 | $14.86 | $10.25 | |
| Revenue / Share | $16.32 | $14.51 | $12.63 | $11.09 | $10.10 | $9.71 | $9.52 | $8.41 | $7.53 | $6.72 | · | · | |
| Cash Flow / Share | $4.19 | $2.91 | $0.83 | $0.93 | $1.67 | $0.45 | $0.27 | $0.11 | $-0.05 | $-1.37 | · | · | |
| Cash / Share | $6.82 | $4.94 | $4.00 | $3.89 | $3.19 | $3.57 | $2.43 | $2.77 | $3.40 | $2.37 | $2.46 | $5.87 | |
| EPS (TTM) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | · | 192,032,000 | 191,907,000 | 190,967,000 | · | 190,429,000 | 190,114,000 | 188,866,000 | · | 188,219,000 | 187,948,000 | 186,667,000 | · | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | · | 192,032,000 | 197,091,000 | 196,474,000 | · | 197,147,000 | 200,505,000 | 199,262,000 | · | 191,173,000 | 194,998,000 | 194,363,000 | · | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | · |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | · | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | · | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | · | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | · | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | · | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | · | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | · | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | · | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | · |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.66 | $32.14 | · | $31.53 | $31.39 | $30.21 | · | $28.41 | $27.77 | $26.74 | · | $26.00 | $25.42 | $24.83 | · | · | |
| Revenue / Share | $5.09 | $3.88 | · | $4.04 | $4.19 | $3.79 | · | $3.78 | $3.55 | $3.26 | · | $3.04 | $3.05 | $3.07 | · | · | |
| Cash Flow / Share | · | $1.12 | · | · | · | $0.89 | · | · | · | $0.24 | · | · | · | $-0.38 | · | · | |
| Cash / Share | $4.52 | $11.50 | · | $6.51 | $6.32 | $5.47 | · | $3.54 | $5.11 | $3.94 | · | $4.17 | $3.69 | $3.09 | · | · | |
| EPS (TTM) | $0.39 | $1.39 | · | $2.67 | $3.38 | $2.70 | · | $1.66 | $1.32 | $1.06 | · | $0.78 | $0.53 | $0.39 | · | $0.43 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.41B | $3.24B | · | $3.09B | $3.06B | $2.95B | · | $2.75B | $2.59B | $2.47B | · | $2.31B | $2.23B | $2.17B | · | $2.01B | |
| Net Income TTM | $73M | $269M | · | $520M | $657M | $524M | · | $322M | $257M | $205M | · | $147M | $100M | $72M | · | $84M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | · | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 146.7 | 40.6 | · | 20.3 | 16.3 | 26.2 | · | 42.3 | 62.4 | 82.4 | · | 113.4 | 163.5 | 249.3 | · | 197.1 | |
| P/S | 3.3 | 3.4 | · | 3.4 | 3.4 | 4.6 | · | 4.9 | 6.1 | 6.7 | · | 7.2 | 7.3 | 8.4 | · | · | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | · | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| EV / Revenue | 4.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.68% | 2.5% | · | 4.9% | 6.2% | 3.8% | · | 2.4% | 1.6% | 1.2% | · | 0.88% | 0.61% | 0.40% | · | 0.51% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Betriebsgewinnmarge % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Nettoergebnis | $349M | $427M | $168M | $142M | $-64M |
| Verwässerte EPS | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $725M | $487M | $63M | $55M | $209M |
Institutionelle Eigentümer (13F) 617 Einreicher · $12.2B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
617
Gehaltener Wert
$12.2B
Neue Positionen
89
Geschlossene Positionen
75
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 89 (-16 vs. Vorquartal) | 75 (+10 vs. Vorquartal) | 209 (+1 vs. Vorquartal) | 198 (+29 vs. Vorquartal) | +10.2M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $1.169.875.004 | 20.445.212 | 9,56% | Aktien |
| VANGUARD GROUP INC | $1.077.337.946 | 18.127.847 | 8,80% | Aktien |
| Dodge & Cox | $849.426.895 | 14.844.930 | 6,94% | Aktien |
| PRIMECAP MANAGEMENT CO/CA/ | $811.962.329 | 14.190.183 | 6,63% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $500.310.680 | 8.743.633 | 4,09% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494.877.355 | 8.648.678 | 4,04% | Aktien |
| NORGES BANK | $469.659.128 | 8.207.954 | 3,84% | Aktien |
| STATE STREET CORP | $446.370.874 | 7.800.959 | 3,65% | Aktien |
| VIKING GLOBAL INVESTORS LP | $435.819.735 | 7.616.563 | 3,56% | Aktien |
| Vestal Point Capital, LP | $344.750.500 | 6.025.000 | 2,82% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $322.537.038 | 5.699.541 | 2,64% | Aktien |
| FMR LLC | $275.965.970 | 4.822.893 | 2,25% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $233.217.034 | 4.075.714 | 1,91% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $223.885.722 | 3.911.794 | 1,83% | Aktien |
| Capital Research Global Investors | $200.521.024 | 3.504.387 | 1,64% | Aktien |
| Deep Track Capital, LP | $189.254.063 | 3.307.481 | 1,55% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $118.549.312 | 2.071.816 | 0,97% | Aktien |
| Assenagon Asset Management S.A. | $100.826.561 | 1.762.086 | 0,82% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $92.468.664 | 1.616.020 | 0,76% | Aktien |
| FIRST TRUST ADVISORS LP | $91.910.897 | 1.606.273 | 0,75% | Aktien |
| NORTHERN TRUST CORP | $89.154.711 | 1.558.104 | 0,73% | Aktien |
| MORGAN STANLEY | $86.115.553 | 1.504.989 | 0,70% | Aktien |
| Jones Hill Capital LP | $81.915.580 | 1.431.590 | 0,67% | Aktien |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76.264.876 | 1.332.836 | 0,62% | Aktien |
| Swedbank AB | $75.232.112 | 1.314.787 | 0,61% | Aktien |
| UBS Group AG | $73.613.817 | 1.286.505 | 0,60% | Aktien |
| DNB Asset Management AS | $72.566.061 | 1.268.194 | 0,59% | Aktien |
| Caisse de depot et placement du Quebec | $70.749.440 | 1.236.446 | 0,58% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $70.030.356 | 1.223.879 | 0,57% | Aktien |
| GOLDMAN SACHS GROUP INC | $68.777.119 | 1.201.977 | 0,56% | Aktien |
| AMERIPRISE FINANCIAL INC | $66.255.506 | 1.157.865 | 0,54% | Aktien |
| Bank of New York Mellon Corp | $66.106.543 | 1.155.305 | 0,54% | Aktien |
| CITADEL ADVISORS LLC | $64.224.186 | 1.122.408 | 0,52% | Aktien |
| Balyasny Asset Management L.P. | $60.344.956 | 1.054.613 | 0,49% | Aktien |
| ARGA Investment Management, LP | $59.474.983 | 1.039.409 | 0,49% | Aktien |
| Brandywine Global Investment Management, LLC | $56.211.687 | 945.847 | 0,46% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54.484.884 | 952.200 | 0,45% | Kaufoption |
| FRANKLIN RESOURCES INC | $53.560.439 | 936.044 | 0,44% | Aktien |
| MACKENZIE FINANCIAL CORP | $53.321.258 | 931.864 | 0,44% | Aktien |
| JANUS HENDERSON GROUP PLC | $48.409.915 | 857.010 | 0,40% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $48.062.765 | 850.819 | 0,39% | Aktien |
| Hudson Bay Capital Management LP | $47.206.614 | 825.002 | 0,39% | Aktien |
| Russell Investments Group, Ltd. | $44.813.913 | 783.148 | 0,37% | Aktien |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40.949.264 | 715.646 | 0,33% | Aktien |
| LOOMIS SAYLES & CO L P | $40.835.454 | 713.657 | 0,33% | Aktien |
| JPMORGAN CHASE & CO | $40.573.267 | 694.550 | 0,33% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39.869.980 | 696.784 | 0,33% | Aktien |
| Nuveen, LLC | $39.432.077 | 689.131 | 0,32% | Aktien |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39.311.857 | 687.030 | 0,32% | Aktien |
| Palo Alto Investors LP | $39.068.500 | 682.777 | 0,32% | Aktien |
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 Einreichungen | 2. Februar 2015 | · | Erste Einreichung | · | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 Einreichungen | 31. Juli 2009 | · | Erste Einreichung | · | SEC |
| 6. Juni 2005 | · | Erste Einreichung | Vorstandskampagne | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 Einreichungen | 6. Mai 2005 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 50 Insider · 21 Führungskräfte · 30 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17. März 2026 F | 214.635 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 2. Mai 2005 A | 14.934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 6. Mai 2004 P | 79.285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17. März 2026 F | 123.314 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 30. April 2019 A | 47.686 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14. Mai 2012 M | 41.089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13. September 2024 F | 185.074 | 0 | 0 | $0 |
| Robert Baffi | President, Global Mfg/Tech Ops | 20. März 2020 F | 117.138 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 30. September 2026 F | 47.732 | 0 | 2 | $-558.646 |
| George Eric Davis | EVP, Chief Legal Officer | 2. September 2026 S | 61.003 | 0 | 2 | $-2.762.781 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20. Mai 2026 F | 42.472 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17. März 2026 F | 84.140 | 0 | 1 | $-996.744 |
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | 20. Januar 2026 A | 25.610 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20. Mai 2025 S | 14.173 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 2. Mai 2024 S | 66.767 | 0 | 0 | $0 |
| Andrea Acosta | GVP, Chief Accounting Officer | 16. Juli 2021 F | 18.122 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 2. Juli 2012 M | 59.030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 2. März 2009 M | 39.621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 7. Juli 2008 A | 12.000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 1. Dezember 2005 M | 295.176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31. Oktober 2004 A | 2.740 | 0 | 0 | $0 |
| Robert M Plenge | Direktor | 10. September 2026 A | 6.140 | 0 | 0 | $0 |
| Elizabeth M Anderson | Direktor | 2. Juni 2026 A | 41.940 | 0 | 0 | $0 |
| Barbara W. Bodem | Direktor | 2. Juni 2026 A | 21.045 | 0 | 0 | $0 |
| Maykin Ho | Direktor | 2. Juni 2026 A | 35.500 | 0 | 0 | $0 |
| Mark J Enyedy | Direktor | 2. Juni 2026 A | 21.040 | 0 | 0 | $0 |
| Athena Countouriotis | Direktor | 2. Juni 2026 A | 21.040 | 0 | 0 | $0 |
| Robert J. Hombach | Direktor | 2. Juni 2026 A | 49.360 | 0 | 0 | $0 |
| Timothy P Walbert | Direktor | 2. Juni 2026 A | 17.270 | 0 | 0 | $0 |
| Ian T Clark | Direktor | 2. Juni 2026 A | 14.490 | 0 | 0 | $0 |
| Willard H Dere | Direktor | 2. Juni 2026 A | 46.440 | 0 | 0 | $0 |
| Richard A Meier | Direktor | 20. Mai 2025 A | 127.426 | 0 | 0 | $0 |
| Elaine J Heron | Direktor | 3. Juni 2024 M | 97.720 | 0 | 0 | $0 |
| David E I Pyott | Direktor | 21. Mai 2024 A | 49.750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Direktor | 20. Mai 2024 F | 473.792 | 0 | 0 | $0 |
| Dennis Slamon | Direktor | 18. März 2024 M | 31.299 | 0 | 0 | $0 |
| Mark J Alles | Direktor | 23. Mai 2023 A | 15.095 | 0 | 0 | $0 |
| Bryan V Lawlis | Direktor | 23. Mai 2023 A | 33.140 | 0 | 0 | $0 |
| Michael G Grey | Direktor | 5. März 2021 M | 42.840 | 0 | 0 | $0 |
| Alan Lewis | Direktor | 4. Juni 2019 A | 25.590 | 0 | 0 | $0 |
| Kathryn E Falberg | Direktor | 15. Juli 2016 A | 2.640 | 0 | 0 | $0 |
| William D Young | Direktor | 10. Juni 2015 A | 11.875 | 0 | 0 | $0 |
| Kenneth Bate | Direktor | 10. Juni 2015 A | 11.875 | 0 | 0 | $0 |
| Pierre Lapalme | Direktor | 10. Juni 2015 A | 31.250 | 0 | 0 | $0 |
| Joseph Klein III | Direktor | 8. März 2010 S | 35.000 | 0 | 0 | $0 |
| Franz L Cristiani | Direktor | 14. Juni 2006 A | · | 0 | 0 | $0 |
| Erich Sager | Direktor | 24. Februar 2006 M | 3.309 | 0 | 0 | $0 |
| Gwynn Williams | Direktor | 30. November 2004 A | 812.565 | 0 | 0 | $0 |
| John Urquhart | Direktor | 28. Juli 2004 A | · | 0 | 0 | $0 |
| Mark Wood | · | 22. Mai 2013 M | 20.277 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 81 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,51% | 177.471 SH | 1. Oktober 2026 | Täglich |
| BBP · ETFis Series Trust I | 1,48% | 24.255 NS | 31. Juli 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,31% | 15.080 NS | 31. Juli 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,17% | 41.384 NS | 31. Juli 2026 | N-PORT |
| RNIN · EA Series Trust | 1,15% | 35.050 NS | 31. Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,92% | 1.454.497 SH | 11. September 2026 | Täglich |
| CALF · Pacer Funds Trust | 0,79% | 482.285 NS | 31. Juli 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,76% | 30.936 NS | 31. Juli 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,76% | 13.701 SH | 1. Oktober 2026 | Täglich |
| LABU · Direxion Shares ETF Trust | 0,73% | 60.076 NS | 31. Juli 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,44% | 77.415 NS | 31. Juli 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,44% | 24.133 NS | 31. Juli 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,38% | 26.065 SH | 1. Oktober 2026 | Täglich |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 108.709 SH | 19. August 2026 | Täglich |
| PTMC · Pacer Funds Trust | 0,33% | 21.272 NS | 31. Juli 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,32% | 436.803 NS | 31. Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,30% | 2.559.860 SH | 19. August 2026 | Täglich |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,30% | 312.378 SH | 19. August 2026 | Täglich |
| BKMC · BNY Mellon ETF Trust | 0,28% | 29.895 NS | 31. Juli 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,27% | 71.381 SH | 19. August 2026 | Täglich |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,25% | 84.704 NS | 31. Juli 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,25% | 2.838 NS | 31. Juli 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,20% | 821 NS | 31. Juli 2026 | N-PORT |
| IYH · iShares Trust | 0,20% | 111.984 SH | 11. September 2026 | Täglich |
| SMMD · iShares Trust | 0,17% | 102.244 SH | 11. September 2026 | Täglich |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,17% | 16.041 NS | 31. Juli 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,16% | 19.998 SH | 19. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,16% | 401.829 NS | 31. Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,15% | 84.531 NS | 31. Juli 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,15% | 534.462 SH | 19. August 2026 | Täglich |
| ISCG · iShares Trust | 0,15% | 21.366 SH | 11. September 2026 | Täglich |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 20.990 SH | 19. August 2026 | Täglich |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,13% | 28.086 SH | 1. Oktober 2026 | Täglich |
| ESML · iShares Trust | 0,13% | 56.252 SH | 11. September 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,13% | 4.433.137 SH | 19. August 2026 | Täglich |
| IWS · iShares Trust | 0,12% | 286.469 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,12% | 2.217.617 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,11% | 11.104 SH | 11. September 2026 | Täglich |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3.901 NS | 31. Juli 2026 | N-PORT |
| PEXL · Pacer Funds Trust | 0,09% | 797 NS | 31. Juli 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 787.222 SH | 11. September 2026 | Täglich |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 11.519 SH | 1. Oktober 2026 | Täglich |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 18.000 NS | 31. Juli 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 5.934 NS | 31. Juli 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,06% | 143.957 NS | 31. Juli 2026 | N-PORT |
| FBUF · Fidelity Greenwood Street Trust | 0,05% | 212 NS | 31. Juli 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,05% | 41.047 SH | 1. Oktober 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 4.814 NS | 31. Juli 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,05% | 18.819 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,04% | 347.063 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,03% | 19.135 NS | 31. Juli 2026 | N-PORT |
| IWD · iShares Trust | 0,03% | 425.477 SH | 11. September 2026 | Täglich |
| DSI · iShares Trust | 0,03% | 27.701 SH | 11. September 2026 | Täglich |
| REVS · Columbia ETF Trust I | 0,03% | 1.740 NS | 31. Juli 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 115.700 SH | 19. August 2026 | Täglich |
| DFUV · Dimensional ETF Trust | 0,03% | 74.321 NS | 31. Juli 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,03% | 45.172 SH | 1. Oktober 2026 | Täglich |
| TILT · FlexShares Trust | 0,03% | 9.322 NS | 31. Juli 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,02% | 3.375 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 44.514 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 6.143.206 SH | 19. August 2026 | Täglich |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 31.861 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 16.031 SH | 19. August 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,02% | 43.345 SH | 19. August 2026 | Täglich |
| IUSG · iShares Trust | 0,02% | 97.914 SH | 11. September 2026 | Täglich |
| IWB · iShares Trust | 0,02% | 130.403 SH | 11. September 2026 | Täglich |
| IYY · iShares Trust | 0,02% | 8.059 SH | 11. September 2026 | Täglich |
| ITOT · iShares Trust | 0,02% | 253.576 SH | 11. September 2026 | Täglich |
| IUSV · iShares Trust | 0,02% | 71.403 SH | 11. September 2026 | Täglich |
| RECS · Columbia ETF Trust I | 0,02% | 16.398 NS | 31. Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,02% | 51.240 SH | 11. September 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,02% | 53.858 NS | 31. Juli 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 169.270 SH | 19. August 2026 | Täglich |
| DFLV · Dimensional ETF Trust | 0,00% | 1.028 NS | 31. Juli 2026 | N-PORT |
| IJH · iShares Trust | · | 6.782.201 SH | 11. September 2026 | Täglich |
| IJK · iShares Trust | · | 638.802 SH | 11. September 2026 | Täglich |
| IJJ · iShares Trust | · | 423.789 SH | 21. August 2026 | Täglich |
| XJH · iShares Trust | · | 26.404 SH | 8. September 2026 | Täglich |
| ISCB · iShares Trust | · | 8.699 SH | 11. September 2026 | Täglich |
| ISCV · iShares Trust | · | 27.848 SH | 11. September 2026 | Täglich |
| SMMV · iShares Trust | · | 29.688 SH | 19. August 2026 | Täglich |
BMRN Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 35 Analysten
KAUF
Median-Ziel
$90.00
+57,4%
10 28,6%
Starker Kauf
17 48,6%
Kauf
8 22,9%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
26 Analysten · 2026-10-02Mittelwert-Ziel $91.62 +60,2%
← Unter allen Zielen
Aktueller Preis $57.18
Tief$60.00
Mittelwert$91.62
Hoch$124.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
| IBRX | $2.00B | -5.2 | 668.3% | -310.2% | 71.0% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
Yahoo Finance · 3 Monate, 3 Wochen vor
Ist BioMarin Pharmaceutical Inc. (BMRN) eine der Top-billigen Aktien, die man mit dem größten Aufwärtspotenzial kaufen kann?
Yahoo Finance · 4 Monate, 3 Wochen vor
BioMarin ernennt Ian Clark zum Vorstandsvorsitzenden
Nasdaq · 5 Monate, 1 Woche vor
BioMarin Pharmaceutical (BMRN) berichtet über positive Ergebnisse aus laufenden Studien zu VOXZOGO
Yahoo Finance · 6 Monate, 1 Woche vor
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
BLUECHIP_DIP
Stop-Loss ausgelöst
Risiko 1
Belohnung 4,99
Einstieg
$54.11
R:R 4,99
BLUECHIP_DIP
Stop-Loss ausgelöst
Risiko 1
Belohnung 4,80
Einstieg
$54.99
R:R 4,80
BLUECHIP_DIP
Stop-Loss ausgelöst
Risiko 1
Belohnung 5,00
Einstieg
$56.36
R:R 5,00
Derzeit kein offenes Signal – keine Karte ist ausgefüllt, und das ist ehrlich.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026